Use of sacubitril/valsartan as 'bridge to transplant' in patients with end-stage hypertrophic cardiomyopathy.

Abstract

The end stage or burned-out phase is an uncommon but challenging clinical evolution of hypertrophic cardiomyopathy (HCM). The management of end-stage HCM is empirically based on the use of drugs approved for heart failure with reduced ejection fraction; however, cardiac transplantation often represents the best option to improve survival. In our case, we describe the use of sacubitril/valsartan as a 'bridge to transplant' in a patient with end-stage HCM. After introducing the drug, enhancements in functional capacity, a reduction in natriuretic peptides and an increase in left ventricular ejection fraction occurred. Given their improved volume of oxygen consumption (VO2) peak and hemodynamic parameters, our patient was left off the waiting list for cardiac transplant and continues to be regularly followed-up with every 3 months.

• Authors: Daniele Masarone, Enrico Melillo, Fabio Valente, Andrea Petraio, Giuseppe Limongelli, Marina Verrengia, Rita Gravino, Ernesto Ammendola, Giuliano D'Alterio, Rossella Vastarella, Giuseppe Pacileo
• Journal: Future cardiology (Future Cardiol) Vol. 17 Issue 1 Pg. 89-94 (01 2021) ISSN: 1744-8298 [Electronic] England
• PMID: 32723181 (Publication Type: Journal Article)

Chemical References

• Aminobutyrates
• Angiotensin Receptor Antagonists
• Biphenyl Compounds
• Drug Combinations
• Valsartan
• sacubitril and valsartan sodium hydrate drug combination

Topics

• Aminobutyrates
• Angiotensin Receptor Antagonists (therapeutic use)
• Biphenyl Compounds
• Cardiomyopathy, Hypertrophic (drug therapy)
• Drug Combinations
• Heart Failure (drug therapy)
• Humans
• Stroke Volume
• Valsartan
• Ventricular Function, Left